Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01602419|
Recruitment Status : Completed
First Posted : May 21, 2012
Last Update Posted : January 29, 2018
|Condition or disease||Intervention/treatment|
|Von Willebrand Disease||Other: Patients using wilate as standard of care|
|Study Type :||Observational|
|Actual Enrollment :||120 participants|
|Official Title:||Surveillance of Safety and Efficacy of Wilate in Patients With Von Willebrand Disease|
|Actual Study Start Date :||October 2012|
|Actual Primary Completion Date :||December 2017|
|Actual Study Completion Date :||December 2017|
Patients using wilate as standard of care treatment
This patient population is being treated with wilate as standard of care treatment
Other: Patients using wilate as standard of care
Patients with von Willebrand Disease using wilate for a period of 2 years.
- Safety and tolerability [ Time Frame: 2 years per patient ]Document safety and tolerability (Adverse Events, vital signs, tolerability of the infusion) of wilate for prophylaxis and treatment of bleeding in von Willebrand Disease (VWD), including surgeries
- Efficacy [ Time Frame: 2 years per patient ]Document the efficacy of wilate in the treatment of acute bleeding, in the prophylaxis of VWD and in interventional procedures (e.g. minor/major surgery, dental care, invasive diagnostic procedures.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01602419
Show 24 Study Locations